

Systemic side effects of glaucoma medications

Australasian journal of optometry, The
105, 157-165

DOI: [10.1080/08164622.2021.1964331](https://doi.org/10.1080/08164622.2021.1964331)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ocular implications of systemic disease. Australasian journal of optometry, The, 2022, 105, 103-104.	1.3	0
2	Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Frontiers in Pharmacology, 0, 13, .	3.5	10
3	Synthesis and Molecular Docking of New N-Acyl Hydrazones- Benzimidazole as hCA I and II Inhibitors. Medicinal Chemistry, 2023, 19, 485-494.	1.5	0
4	Prostaglandin F2 \pm Regulates Adipogenesis by Modulating Extracellular Signal-Regulated Kinase Signaling in Graves's™ Ophthalmopathy. International Journal of Molecular Sciences, 2023, 24, 7012.	4.1	0
5	Evaluation of antiglaucoma drug treatment awareness and patient-reported medication adherence: Determinants of glaucoma management. Journal of Postgraduate Medicine, 2023, 69, 146-152.	0.4	1
6	Comparative Effectiveness and Safety of Two Different Trabecular MIGS Devices With and Without Ab Interno Canaloplasty in Patients with Primary Open-Angle Glaucoma. Ophthalmology and Therapy, 0, , .	2.3	0
7	Association between dietary calcium, potassium, and magnesium consumption and glaucoma. PLoS ONE, 2023, 18, e0292883.	2.5	0
8	A review of using Traditional Chinese Medicine in the management of glaucoma and cataract. Australasian journal of optometry, The, 0, , 1-15.	1.3	0
9	Lupane acetates in small molecule drug hybrids: Probing their inhibitory activity for carbonic anhydrase II. European Journal of Medicinal Chemistry Reports, 2024, 10, 100139.	1.4	0
10	Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists. International Journal of Molecular Sciences, 2024, 25, 3328.	4.1	0